To evaluate the effect of Ranolazine on Fasting Plasma Glucose in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy

Budania, Navin; Kumar, Amit; Sharma, Priyamvada; Saharan, Savita; Kumar, Arun

doi:10.7439/ijbar.v4i10.508

Cited by 1 publication

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study15 has been excluded as it compared ranolazine with trimetazidine, as the latter is known to have significant impact on glucose metabolism,16 instead of placebo. Budania et al 8 has also been excluded from this meta-analysis as it had not explored HbA1c changes in subjects. Therefore, five studies, including six trials, have been selected to enter meta-analysis to study effect of ranolazine on HbA1c.…”

Section: Resultsmentioning

confidence: 99%

“…There is, however, unclear risk for allocation concealment for all studies as there was insufficient description on methods of concealment. There is high risk of performance and detection bias in Budania et al 8 as it was an open-labelled trial. Eckel et al 18 and Timmis et al were deemed to be at high risk of reporting bias as they did not use intention-to-treat analysis.…”

Section: Resultsmentioning

confidence: 99%

“…The demographic details of the study participants are summarised in online supplementary table S1, and concomitant antidiabetic medications used in patients with diabetes in these trials are detailed in online supplementary table S2. Six of these seven trials except Budania et al 8, which did not include data on HbA1c, were included in meta-analysis of effect of ranolazine on HbA1c. Six of these seven trials except Morrow et al , which did not include data on FPG, were included in meta-analysis of effect of ranolazine on FPG.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials

Teoh

Banerjee

2018

Open Heart

View full text Add to dashboard Cite

BackgroundRanolazine is an antianginal drug reported to have hypoglycaemic effects.ObjectivesTo assess the effect of ranolazine versus placebo on glycaemic control for adults with and without diabetes.MethodsA systematic search of seven databases was conducted to identify all randomised controlled trials that compared the effect of ranolazine versus placebo on haemoglobin A1c (HbA1c) and/or fasting plasma glucose (FPG) and/or incidence of hypoglycaemia. We used mean differences in HbA1c and FPG to express intervention effect estimates and analysed the data with random-effects model for meta-analyses using Revman 5.3.ResultsWe identified seven trials including 6543 subjects to assess the effect of ranolazine on HbA1c and/or FPG. A separate trial that included 944 subjects was included to assess the effect of ranolazine on hypoglycaemia. The change in HbA1c for all patients was −0.36% (95% CI −0.57% to −0.15%; p=0.0004, I2=78%). In patients with diabetes, the change in HbA1c was −0.41% (95% CI −0.58% to −0.25%; p<0.00001, I2=65%). There was no significant difference in FPG between ranolazine and placebo groups (−2.58 mmol/L, 95% CI −7.02 to 1.85; p=0.25; I2=49%) or incidence of hypoglycaemia between ranolazine and placebo groups (OR 1.70, 95% CI 0.89 to 3.26; p=0.61, I2=0%).ConclusionsOur meta-analytic findings support the fact that ranolazine improves HbA1c without increasing the risk of hypoglycaemia. It therefore has a potential of having an additional benefit of improving glycaemic control in patients with chronic stable angina and diabetes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation